EANS-News: EPIGENOMICS AG Releases 9-Months Financial Report

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Company Information/9-month report/Molecular diagnostics

Berlin, Germany, November 9, 2010 (euro adhoc) - Epigenomics AG
(Frankfurt Prime Standard: ECX) reports today its third quarter and
nine months financials for the period ended September 30, 2010.

Key Financials

| | |Q3/10 |9M/10 | 9M/09 |% change |
| | |(unaudited)|(unaudited)|(unaudited)|(9M) |
| | | | | | |
|Revenue |in mill. |0.36 |1.34 |3.2(1) |-58% |
| |EUR | | | | |
|EBIT |in mill. |-3.01 |-8.44 |-7.1 |19% |
| |EUR | | | | |
|Net Loss |in mill. |-3.00 |-8.36 |-7.1 |18% |
| |EUR | | | | |
|Liquid Assets |in mill. | |29.61(2) |9.5 | |
| |EUR | | | | |

1) Includes non-recurrent payments in R&D and licensing partnerships in
2009.
2) Difference due to the raising of gross proceeds of approx. EUR 33.1
million in a capital increase in early 2010

Operational Highlights in the Reporting Period
• Dual track commercial strategy rolling out in Europe & US and key
highlights during the 9 month period included:
o Direct sales: Epi proColon kits available nationwide in Germany and
Switzerland
o Partners´ sales: colorectal cancer blood tests based on Septin9
available in the US through Quest Diagnostics and ARUP Laboratories,
and Abbott (EU and Asia/Pacific)
o New non-exclusive licensing agreement signed with Warnex for
Canadian market, expected launch by the end of 2010
• Tests now being shipped to customers internationally
• Positive clinical data published at leading scientific conferences
worldwide including results of the successfully completed prospective
PRESEPT Study at the 2010 Digestive Disease Week
• Launched new lung cancer diagnostic test, Epi proLung BL Reflex Assay, in
Europe after successful completion of pivotal performance evaluation study

Post Period End Events

• Exclusive distribution deals signed with Pronto Diagnostics, DATEKs and
DPC for commercialization of Epi proColon in the entire Middle East region
• Further positive clinical validation studies
o ARUP presented data demonstrating that its Septin9 laboratory-
developed test has 90% sensitivity for cancer at 89% specificity at
ASCO-NI-EORTC meeting
o Epigenomics presented new data generated by an independent
laboratory with the PRESEPT Septin9 assay at the UEGW as well as
AACR meetings showing sensitivity of 86% at specificity of 93%
• Briefing booklet submitted to FDA on Epi proColon; Epigenomics expects
pre-IDE meeting to take place late 2010 / early 2011
• Allocation of US$ 245,000 grant to Epigenomics as a partial reimbursement
and co-funding of the clinical trial PRESEPT for the fiscal year 2009 under
the Qualifying Therapeutic Discovery Projects (QTDP)

program by the US Internal Revenue Service. The QTDP program is
funded through the Patient Protection and Affordable Care Act.

Geert Nygaard, Chief Executive Officer of Epigenomics said: "We are
proud of Epigenomics´ extensive operational achievements so far this
year. Our dual track commercial strategy is developing well with new
partners and distributors on board giving us access to new markets
and countries with our test and technology. We are also seeing very
positive clinical data which are reinforcing the independent view
that blood-based colorectal cancer tests are going to become an
essential method of screening for patients in the future."

He added: "Sales growth is taking longer than expected due to slower
initial uptake of our test and this is likely going to continue at a
gradual pace during 2011. However, we are taking proactive steps to
reach out to the medical profession about the benefits of the test to
patients. In addition, with the recent funding of EUR33.1m gross
proceeds, the Company is in a solid financial position to support the
commercial strategy at this early stage and in bringing new partners
on board."

The full 9-Months Financial Report 2010 is available for download at
www.epigenomics.com/en/investor_relations/Financial_Information/

The Company´s management will be available for analyst and investor
meetings at the upcoming Lazard Capital Markets 7th Annual Healthcare
Conference in New York, USA, on November 16-17, 2010 and the German
Equity Forum 2010 in Frankfurt am Main, Germany, on November 22-23,
2010.

-Ends-
Notes to the Editor

|Contact Epigenomics AG |
|Dr. Achim Plum |
|Sen. VP Corporate Development |
|Epigenomics AG |
|Tel +49 (0) 30 24345 368 |
|pr@epigenomics.com |
|www.epigenomics.com |

Conference Details

Lazard Capital Markets 7th Annual Healthcare Conference
Epigenomics´ presentation on November 16, 2010 at 10:25 am EST
The St. Regis Hotel, 22 East 55th Street, New York, USA

German Equity Forum 2010 Epigenomics´ presentation on November 23,
2010 at 12:00 noon CET, Room Madrid, Congress Center, Messe
Frankfurt, Ludwig-Erhard-Anlage 1, Frankfurt am Main, Germany

About Epigenomics

Epigenomics AG is a molecular diagnostics company with a focus on the
development of novel products for cancer. Using DNA methylation
biomarkers, Epigenomics´ tests on the market and in development for
colorectal, lung, and prostate cancer aim at aiding in an earlier and
more accurate diagnosis of these diseases thereby potentially
increasing the patient´s chances of survival.

For development and global commercialization of IVD test products,
Epigenomics pursues a dual business strategy in which direct
commercialization of proprietary diagnostic test products is combined
with non-exclusive licensing to diagnostic industry players with
broad customer access. Strategic diagnostics industry partners
include Abbott Molecular, Sysmex Corporation, Quest Diagnostics
Incorporated, ARUP Laboratories, Inc., and Warnex Laboratories, Inc.
for diagnostics test products and services, and QIAGEN N.V. for
sample preparation solutions and research products. The company is
headquartered in Berlin, Germany, and has a wholly owned subsidiary,
Epigenomics Inc., in Seattle, WA, USA. For more information, please
visit Epigenomics´ website at www.epigenomics.com.

Epigenomics´ legal disclaimers. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States of America. The analytical and
clinical performance characteristics of any product based on this
technology which may be sold at some future time in the USA have not
been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade